一种用于婴儿初次免疫的新型B型流感嗜血杆菌和C群脑膜炎奈瑟菌-破伤风类毒素结合疫苗。
A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.
作者信息
Pace David, Snape Matthew, Westcar Sharon, Hamaluba Mainga, Yu Ly-Mee, Begg Norman, Wysocki Jacek, Czajka Hanna, Maechler Gudrun, Boutriau Dominique, Pollard Andrew J
机构信息
Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK.
出版信息
Pediatr Infect Dis J. 2007 Nov;26(11):1057-9. doi: 10.1097/INF.0b013e31813429fa.
We conducted a phase 3 randomized controlled trial looking at the immunogenicity and safety of a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine, Hib-MenC-TT in a 2-, 3-, and 4-month primary infant immunization schedule. SBA MenC titers > or =1:8 and anti-PRP concentrations > or =0.15 microg/mL were measured in 99.2% and 100%, respectively, of the infants receiving Hib-MenC-TT.
我们进行了一项3期随机对照试验，研究一种新型的b型流感嗜血杆菌与C群脑膜炎奈瑟菌破伤风类毒素结合疫苗（Hib-MenC-TT）在2、3、4月龄婴儿基础免疫程序中的免疫原性和安全性。在接受Hib-MenC-TT的婴儿中，分别有99.2%和100%的婴儿检测到SBA MenC滴度≥1:8和抗PRP浓度≥0.15微克/毫升。
Zotero 插件